1. Home
  2. HTCR vs GNPX Comparison

HTCR vs GNPX Comparison

Compare HTCR & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartcore Enterprises Inc.

HTCR

Heartcore Enterprises Inc.

HOLD

Current Price

$2.00

Market Cap

3.5M

Sector

Technology

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$3.45

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTCR
GNPX
Founded
2009
2009
Country
Japan
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
2.9M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
HTCR
GNPX
Price
$2.00
$3.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.3K
39.7K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
87.84%
N/A
EPS Growth
414.29
N/A
EPS
N/A
N/A
Revenue
$30,407,229.00
N/A
Revenue This Year
$123.26
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.19
N/A
52 Week Low
$0.15
$0.16
52 Week High
$3.97
$12.97

Technical Indicators

Market Signals
Indicator
HTCR
GNPX
Relative Strength Index (RSI) 39.12 42.37
Support Level $0.23 $1.88
Resistance Level $3.77 $3.56
Average True Range (ATR) 0.19 0.19
MACD -0.01 0.01
Stochastic Oscillator 29.12 31.03

Price Performance

Historical Comparison
HTCR
GNPX

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: